Search - tctmd.com

Displaying 1 - 20 of 33

Sort: Relevancy | Date

Too Few HF Patients on Guideline-Directed Medical Therapy in VA System

News Conference News HFSA 2025

Too Few HF Patients on Guideline-Directed Medical Therapy in VA System

Yael L. Maxwell

October 06, 2025

Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM

News Conference News HFSA 2025

Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM

Yael L. Maxwell

October 01, 2025

Lowering Novel Biomarker, GDF-15, Raises HF Event Rate: GARDEN-TIMI 74

News Conference News HFSA 2025

Lowering Novel Biomarker, GDF-15, Raises HF Event Rate: GARDEN-TIMI 74

Yael L. Maxwell

September 30, 2025

CCM-D Delivers Safe, Effective Integrated Therapy in HFrEF

News Conference News HFSA 2025

CCM-D Delivers Safe, Effective Integrated Therapy in HFrEF

Yael L. Maxwell

September 29, 2025

Voice Analysis Picks Up Patients at Risk for HF Hospitalization: COMMUNITY-HF

News Conference News HFSA 2025

Voice Analysis Picks Up Patients at Risk for HF Hospitalization: COMMUNITY-HF

Yael L. Maxwell

September 29, 2025

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

News Conference News HFSA 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

October 04, 2024

EXPANDed: Atrial Secondary MR Patients Get Clinical Benefit From TEER

News Conference News HFSA 2024

EXPANDed: Atrial Secondary MR Patients Get Clinical Benefit From TEER

October 03, 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

News Conference News HFSA 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

Michael O'Riordan

October 03, 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

October 02, 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

Innovation in Heart Donation, Preservation Set to Shake Up Allocation

News Conference News HFSA 2023

Innovation in Heart Donation, Preservation Set to Shake Up Allocation

October 18, 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

News Conference News HFSA 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

October 18, 2023

ANTHEM-HFrEF Fails to Show Benefit of Vagal Nerve Stimulation Over GDMT

News Conference News HFSA 2023

ANTHEM-HFrEF Fails to Show Benefit of Vagal Nerve Stimulation Over GDMT

Yael L. Maxwell

October 16, 2023

Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships

News Conference News HFSA 2023

Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships

October 13, 2023

PA Pressure Monitoring Benefits HF Patients With No Recent Hospitalization

News Conference News HFSA 2023

PA Pressure Monitoring Benefits HF Patients With No Recent Hospitalization

October 12, 2023

REBALANCE-HF Uncovers HFpEF Group That Responds to Splanchnic Nerve Ablation

News Conference News HFSA 2023

REBALANCE-HF Uncovers HFpEF Group That Responds to Splanchnic Nerve Ablation

October 11, 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

October 11, 2023

No Benefit of LAA Ligation During HeartMate 3 Implantation: MOMENTUM 3

News Conference News HFSA 2022

No Benefit of LAA Ligation During HeartMate 3 Implantation: MOMENTUM 3

Yael L. Maxwell

October 07, 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

News Conference News HFSA 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

October 07, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.